[Clinical evaluation of the use of proglumide in the treatment of the peptic ulcer semebrome].

The authors have made a clinical evaluation of Proglumida in 27 patients suffering from Peptic ulcer. Proglumida was administered orraly, 2 tables of 200 mg 3 times a day, 1.200 mg in 24 hours, during a period varying from 21 to 28 days. The painful symptoms improved in 96% of the pain occurred in 59% during the first 7 days of treatment. The dispeptic symptoms improved in all cases, disappearing completely in 74%, but in a slower fashion than the pain, and in 68% of the cases only from the second week of treatment onward. The objectivation of the pain by palpation of the epigastrium improved in all cases and did so in a significant form in 59% of the cases during the first seven days of treatment. No undesireable side effects have been observed in any of the cases. We believe that Proglumida is a pharmacological drug of positive action in the treatment of the ulcer syndrome, because of its favorable action and the absence of secondary side effects.